000142089 001__ 142089
000142089 005__ 20240229105143.0
000142089 0247_ $$2doi$$a10.1002/ijc.31797
000142089 0247_ $$2pmid$$apmid:30110135
000142089 0247_ $$2ISSN$$a0020-7136
000142089 0247_ $$2ISSN$$a1097-0215
000142089 0247_ $$2altmetric$$aaltmetric:47127141
000142089 037__ $$aDKFZ-2018-02319
000142089 041__ $$aeng
000142089 082__ $$a610
000142089 1001_ $$aMatejcic, M.$$b0
000142089 245__ $$aCirculating plasma phospholipid fatty acids and risk of pancreatic cancer in a large European cohort.
000142089 260__ $$aBognor Regis$$bWiley-Liss$$c2018
000142089 3367_ $$2DRIVER$$aarticle
000142089 3367_ $$2DataCite$$aOutput Types/Journal article
000142089 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1550058449_19498
000142089 3367_ $$2BibTeX$$aARTICLE
000142089 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142089 3367_ $$00$$2EndNote$$aJournal Article
000142089 520__ $$aThere are both limited and conflicting data on the role of dietary fat and specific fatty acids in the development of pancreatic cancer. In this study, we investigated the association between plasma phospholipid fatty acids and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. The fatty acid composition was measured by gas chromatography in plasma samples collected at recruitment from375 incident pancreatic cancer cases and375 matched controls. Associations of specific fatty acids with pancreatic cancer risk were evaluated using multivariable conditional logistic regression models with adjustment for established pancreatic cancer risk factors. Statistically significant inverse associations were found between pancreatic cancer incidence and levels of heptadecanoic acid (ORT3-T1 [odds ratio for highest versus lowest tertile] =0.63; 95%CI[confidence interval] = 0.41-0.98; ptrend = 0.036), n-3 polyunsaturated α-linolenic acid (ORT3-T1 = 0.60; 95%CI = 0.39-0.92; ptrend = 0.02) and docosapentaenoic acid (ORT3-T1 = 0.52; 95%CI = 0.32-0.85; ptrend = 0.008). Industrial trans-fatty acids were positively associated with pancreatic cancer risk among men (ORT3-T1 = 3.00; 95%CI = 1.13-7.99; ptrend = 0.029), while conjugated linoleic acids were inversely related to pancreatic cancer among women only (ORT3-T1 = 0.37; 95%CI = 0.17-0.81; ptrend = 0.008). Among current smokers, the long-chain n-6/n-3 polyunsaturated fatty acids ratio was positively associated with pancreatic cancer risk (ORT3-T1 = 3.40; 95%CI = 1.39-8.34; ptrend = 0.007). Results were robust to a range of sensitivity analyses. Our findings suggest that higher circulating levels of saturated fatty acids with an odd number of carbon atoms and n-3 polyunsaturated fatty acids may be related to lower risk of pancreatic cancer. The influence of some fatty acids on the development of pancreatic cancer may be sex-specific and modulated by smoking.
000142089 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000142089 588__ $$aDataset connected to CrossRef, PubMed,
000142089 7001_ $$00000-0001-7404-4549$$aLesueur, F.$$b1
000142089 7001_ $$aBiessy, C.$$b2
000142089 7001_ $$aRenault, A. L.$$b3
000142089 7001_ $$aMebirouk, N.$$b4
000142089 7001_ $$aYammine, S.$$b5
000142089 7001_ $$aKeski-Rahkonen, P.$$b6
000142089 7001_ $$aLi, K.$$b7
000142089 7001_ $$aHémon, B.$$b8
000142089 7001_ $$aWeiderpass, E.$$b9
000142089 7001_ $$aRebours, V.$$b10
000142089 7001_ $$aBoutron-Ruault, M. C.$$b11
000142089 7001_ $$aCarbonnel, F.$$b12
000142089 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b13$$udkfz
000142089 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, V.$$b14$$udkfz
000142089 7001_ $$0P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aKuhn, T.$$b15$$udkfz
000142089 7001_ $$aBoeing, H.$$b16
000142089 7001_ $$aTrichopoulou, A.$$b17
000142089 7001_ $$00000-0002-5558-2437$$aPalli, D.$$b18
000142089 7001_ $$aAgnoli, C.$$b19
000142089 7001_ $$aPanico, S.$$b20
000142089 7001_ $$aTumino, R.$$b21
000142089 7001_ $$00000-0002-8008-5096$$aSacerdote, C.$$b22
000142089 7001_ $$aQuirós, J. R.$$b23
000142089 7001_ $$00000-0001-5256-0163$$aDuell, E. J.$$b24
000142089 7001_ $$aPorta, M.$$b25
000142089 7001_ $$aSánchez, M. J.$$b26
000142089 7001_ $$aChirlaque, M. D.$$b27
000142089 7001_ $$aBarricarte, A.$$b28
000142089 7001_ $$aAmiano, P.$$b29
000142089 7001_ $$00000-0002-6859-4648$$aYe, W.$$b30
000142089 7001_ $$aPeeters, P. H.$$b31
000142089 7001_ $$aKhaw, K. T.$$b32
000142089 7001_ $$00000-0002-5652-356X$$aPerez-Cornago, A.$$b33
000142089 7001_ $$aKey, T. J.$$b34
000142089 7001_ $$aBueno-de-Mesquita, H. B.$$b35
000142089 7001_ $$aRiboli, E.$$b36
000142089 7001_ $$aVineis, P.$$b37
000142089 7001_ $$aRomieu, I.$$b38
000142089 7001_ $$aGunter, M. J.$$b39
000142089 7001_ $$00000-0003-1297-3064$$aChajès, V.$$b40
000142089 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.31797$$gVol. 143, no. 10, p. 2437 - 2448$$n10$$p2437 - 2448$$tInternational journal of cancer$$v143$$x0020-7136$$y2018
000142089 909CO $$ooai:inrepo02.dkfz.de:142089$$pVDB
000142089 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000142089 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000142089 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000142089 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000142089 9141_ $$y2018
000142089 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000142089 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142089 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142089 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142089 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2017
000142089 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142089 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000142089 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142089 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142089 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000142089 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000142089 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2017
000142089 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000142089 980__ $$ajournal
000142089 980__ $$aVDB
000142089 980__ $$aI:(DE-He78)C020-20160331
000142089 980__ $$aUNRESTRICTED